Revir Therapeutics has been awarded a $4.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support…
Articles by Steve Bryson, PhD
The first Huntington’s disease patient has been dosed in a Phase 2/3 clinical trial testing…
Researchers have developed a modified and harmless adeno-associated virus (AAV), called AAV-DB-3, that can efficiently deliver low doses of gene…
Two signaling enzymes, GSK3-beta and ERK1, play opposing roles in the development of Huntington’s disease and may represent new…
Most adults with the genetic defect associated with Huntington’s disease were completely able to perform daily activities and tasks…
Researchers have developed a protein-like polymer — a large, string-like molecule composed of small repeating building blocks — that was…
Blood levels of neurofilament light protein (NfL) in people who carry Huntington’s disease-causing mutations, but aren’t showing symptoms, can…
Examining the amounts of certain microbes in the gut and levels of specific metabolites in the blood may help distinguish…
A high level of education, low to moderate alcohol intake, not smoking, and controlling one’s weight may slow Huntington’s…
An investigational oral therapy from PTC Therapeutics called PTC518 safely and effectively reduces levels of the mutant huntingtin protein…